Phenytoin poisoning
- PMID: 16174888
- DOI: 10.1385/NCC:3:2:161
Phenytoin poisoning
Abstract
Phenytoin toxicity may result from intentional overdose, dosage adjustments, drug interactions, or alterations in physiology. Intoxication manifests predominantly as nausea, central nervous system dysfunction (particularly confusion, nystagmus, and ataxia), with depressed conscious state, coma, and seizures occurring in more severe cases. Cardiac complications such as arrhythmias and hypotension are rare in cases of phenytoin ingestion, but they may be seen in parenteral administration of phenytoin or fosphenytoin. Deaths are unlikely after phenytoin intoxication alone. A greatly increased half-life in overdose due to zero-order pharmacokinetics can result in a prolonged duration of symptoms and thus prolonged hospitalization with its attendant complications. The mainstay of therapy for a patient with phenytoin intoxication is supportive care. Treatment includes attention to vital functions, management of nausea and vomiting, and prevention of injuries due to confusion and ataxia. There is no antidote, and there is no evidence that any method of gastrointestinal decontamination or enhanced elimination improves outcome. Activated charcoal should be considered if the patient presents early; however, the role of multiple-dose activated charcoal is controversial. Experimental studies have proven increased clearance rates, but this effect has not been translated into clinical benefit. There is no evidence that any invasive method of enhanced elimination (such as plasmapheresis, hemodialysis, or hemoperfusion) provides any benefit. This article provides an overview of phenytoin pharmacokinetics and the clinical manifestations of toxicity, followed by a detailed review of the various treatment modalities.
Similar articles
-
Phenytoin overdose complicated by prolonged intoxication and residual neurological deficits.Emerg Med Australas. 2004 Aug;16(4):361-5. doi: 10.1111/j.1742-6723.2004.00629.x. Emerg Med Australas. 2004. PMID: 15283725
-
Treatment of severe intravenous phenytoin overdose with hemodialysis and hemoperfusion.Med Sci Monit. 2008 Dec;14(12):CS145-8. Med Sci Monit. 2008. PMID: 19043374
-
Clinical features and management of poisoning due to phenytoin.Med Toxicol Adverse Drug Exp. 1989 Jul-Aug;4(4):229-45. doi: 10.1007/BF03259910. Med Toxicol Adverse Drug Exp. 1989. PMID: 2671594 Review.
-
Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning--report of two pediatric cases.DICP. 1991 Jun;25(6):646-9. doi: 10.1177/106002809102500615. DICP. 1991. PMID: 1877275
-
Fosphenytoin.Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):695-701. doi: 10.1517/17425250902997975. Expert Opin Drug Metab Toxicol. 2009. PMID: 19473113 Review.
Cited by
-
Effect of Chronic Administration of 5-(3-chlorophenyl)-4-Hexyl-2,4 -Dihydro-3H-1,2,4-Triazole-3-Thione (TP-315)-A New Anticonvulsant Drug Candidate-On Living Organisms.Int J Mol Sci. 2021 Mar 25;22(7):3358. doi: 10.3390/ijms22073358. Int J Mol Sci. 2021. PMID: 33805962 Free PMC article.
-
A Rare Case of Junctional Bradycardia Secondary to Oral Phenytoin.Cureus. 2022 May 23;14(5):e25251. doi: 10.7759/cureus.25251. eCollection 2022 May. Cureus. 2022. PMID: 35755519 Free PMC article.
-
Phenytoin induced sinoatrial bradyarrhythmia in the perioperative period.Indian J Anaesth. 2013 Nov;57(6):628-30. doi: 10.4103/0019-5049.123347. Indian J Anaesth. 2013. PMID: 24403634 Free PMC article. No abstract available.
-
36-year-old Male with Syncope.Clin Pract Cases Emerg Med. 2020 Aug;4(3):272-276. doi: 10.5811/cpcem.2020.6.48419. Clin Pract Cases Emerg Med. 2020. PMID: 32926665 Free PMC article.
-
Transcranial focused ultrasound-mediated unbinding of phenytoin from plasma proteins for suppression of chronic temporal lobe epilepsy in a rodent model.Sci Rep. 2023 Mar 13;13(1):4128. doi: 10.1038/s41598-023-31383-4. Sci Rep. 2023. PMID: 36914775 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources